Status: Recruiting
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Participants needed: 42
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: ARS Pharmaceuticals, Inc.Updated: Oct 2, 2025Locations: 3
Eligibility criteria
Is a male or female between the ages of 18 and 65 years, inclusive. [+12]
Has a history of clinically significant gastrointestinal, renal, hepatic, neurol... [+6]